Insight Molecular Diagnostics (IMDX) Change in Cash (2015 - 2026)

Insight Molecular Diagnostics has reported Change in Cash for 12 years, with the latest figure at $16.4 million in Q1 2026.

• Quarterly Change in Cash fell 26.6% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 113.26% YoY) and the FY2025 annual result came in at $2.6 million, up 424.5% from the prior year.
• Change in Cash advanced to $16.4 million in Q1 2026 per IMDX's latest filing, from -$7.3 million in the prior quarter.
• Over five years, Change in Cash peaked at $24.4 million in Q2 2022 and troughed at -$15.2 million in Q1 2022.
• A 5-year average of -$467647.1 and a median of -$4.4 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2025: Change in Cash slumped 304.27% in 2022, then jumped 681.03% in 2025.
• Over 5 years, Change in Cash stood at -$10.5 million in 2022, then surged by 58.76% to -$4.4 million in 2023, then soared by 221.19% to $5.3 million in 2024, then tumbled by 238.27% to -$7.3 million in 2025, then soared by 325.43% to $16.4 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $16.4 million, -$7.3 million, and -$5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.